National Pork Board Launches “Sabor Season” in Time for Peak Grilling Months
DES MOINES, Iowa, May 27, 2020 /PRNewswire-HISPANIC PR WIRE/ — As summer, grills, and smokers heat up across the U.S., the National Pork Board is launching “Sabor Season,” a virtual social media campaign to bring Hispanic families and communities together nationwide.
Throughout Sabor Season, four Hispanic chefs and a pitmaster will take over the National Pork Board’s “Pork Es Sabor” Hispanic-focused Instagram account to teach LIVE virtual grilling classes.
“Pork continues to be the centerpiece protein in our Latin culture and traditions, which are usually celebrated at the family dinner table or at gatherings with close friends,” said Jose de Jesus, senior director of multicultural marketing at the National Pork Board. “That’s especially true during grilling season when pork chops and ribs are the meat of choice for Hispanics.”
According to Nielsen Research, which conducted a study for the National Pork Board, ribs and pork chops over-index – 114 and 112, respectively – with Latinos during grilling season. “Pork is just a staple in the Latino community,” de Jesus said.
Sabor Season LIVE is a series of free, interactive, virtual classes between chefs and consumers, where Latino families and communities can come together to celebrate, recreate dishes, and learn tips and hacks for grilling or smoking the perfect pork cut. Participants will be able to access the list of recipe ingredients for each upcoming class in advance via the National Pork Board’s Pork Es Sabor social media platforms.
The chefs, who will bring their expertise and favorite grilling and smoking tips to the Sabor Season virtual classes, include:
- Jose Mendin, a five-time James Beard Award nominee and the chef and owner of Pubbelly Sushi and La Placita in Miami
- Roberto Mezanava, a pitmaster from Nashville, Tennessee
- Ana Quincoces, a celebrity chef, food entrepreneur, and cookbook author
- Wesley Avila, a celebrated chef and founder of Guerrilla Tacos in Los Angeles, and author of the cookbook “Guerrilla Tacos: Recipes from the streets of LA”
- Richard Sandoval, chef and global restaurateur, and owner of Maya Restaurant in New York City
Classes will be hosted on Thursdays during the summer, starting on June 4 at 6 p.m. ET, via the National Pork Board’s Pork Es Sabor Instagram Live. In celebration of National Grilling Day, the final class will go live on Wednesday, July 22, at 6 p.m. ET.
Sabor Season will culminate with the crowning of a chef’s recipe as “El Mejor Sabor del Verano,” (Summer’s Best Flavor), voted on by consumers. By voting, consumers will be entered to win a grand prize, a Kamado Big Joe III grill valued at $2,700.
Consumers will also be encouraged to put their grilling or smoking skills to the test by recreating the pork recipes from the class, or by sharing their own and posting photos or videos with the hashtag #SaborSeason for a chance to win one of five Kamado Joe Classic I grills valued at $805 each.
To stay connected on the latest Sabor Season updates, recipe ideas and more information, please visit PorkEsSabor.com/SaborSeason and follow along on social media at @PorkEsSabor on Instagram, Facebook, and Twitter. Join the conversation using #SaborSeason.
About the National Pork Board
The National Pork Board has responsibility for Pork Checkoff-funded research, promotion and consumer information projects and for communicating with pork producers and the public. The Pork Checkoff funds national and state programs in consumer education and marketing, retail and foodservice marketing, export market promotion, production improvement, science and technology, swine health, pork safety, and environmental management and sustainability. For the past half-century, the U.S. pork industry has delivered on its commitment to sustainable production and has made significant strides in reducing the environmental impact of pig farming. Through a legislative national Pork Checkoff, pork producers invest $0.40 for each $100 value of hogs sold. Importers of pork products contribute a like amount, based on a formula. For information on Checkoff-funded programs, pork producers can call the Pork Checkoff Service Center at (800) 456-7675 or visit www.pork.org.
Photo – https://mma.prnewswire.com/media/1173480/Natl_Pork_Board_5_chefs_RGB__Digital.jpg
Logo – https://mma.prnewswire.com/media/332733/logo.jpg
SOURCE National Pork Board
Don’t Transmit– Wear A Mask
WASHINGTON, May 27, 2020 /PRNewswire-HISPANIC PR WIRE/ — “Enjoy the summer and the warm weather. Just don’t transmit— wear a mask,” emphasized Jane L. Delgado, PhD, MS, President and CEO of the National Alliance for Hispanic Health (the Alliance). She added, “In a recent outing in my neighborhood, I was surprised when I saw that only 1 out 5 people walking around were wearing masks.”
The new COVID-19 “Wear a Mask Save a Life Campaign” is the latest resource from the National Alliance for Hispanic Health and can be downloaded for free (www.healthyamericas.org). “In these times of social distancing and isolation inside our homes, it’s important to remind everyone to wear a mask when you go outside. This way you can still enjoy your outdoor activities and protect yourself and others,” said Jane L. Delgado, PhD, MS, President and CEO of the Alliance.
The wear a mask message was developed when Edgar Gil Rico, Senior Director for Innovation and Program Development at the Alliance was out for his daily run and noticed that most people did not use masks. “I run at 5am so as to allow for social distancing but I also use a mask. It was amazing to me how many people were not wearing a mask.” The importance of a mask has many dimensions. “You cannot tell by looking at someone whether or not they are carrying COVID19. Wearing a mask is what we do to protect each other,” emphasized Dr. Delgado.
To download the free messages and other COVID-19 information, go to healthyamericas.org or for the Spanish language version go to nuestrasalud.org.
About the National Alliance for Hispanic Health (The Alliance) — The Alliance is the nation’s foremost science-based source of information and trusted advocate for the health of Hispanics in the United States with a mission to achieve the best health for all. For more information visit us www.healthyamericas.org
Video – https://mma.prnewswire.com/media/1173139/FACEMASK_ENGLISHv2.mp4
SOURCE National Alliance for Hispanic Health
Don’t Transmit– Wear A Mask
WASHINGTON, May 27, 2020 /PRNewswire-HISPANIC PR WIRE/ — “Enjoy the summer and the warm weather. Just don’t transmit— wear a mask,” emphasized Jane L. Delgado, PhD, MS, President and CEO of the National Alliance for Hispanic Health (the Alliance). She added, “In a recent outing in my neighborhood, I was surprised when I saw that only 1 out 5 people walking around were wearing masks.”
The new COVID-19 “Wear a Mask Save a Life Campaign” is the latest resource from the National Alliance for Hispanic Health and can be downloaded for free (www.healthyamericas.org). “In these times of social distancing and isolation inside our homes, it’s important to remind everyone to wear a mask when you go outside. This way you can still enjoy your outdoor activities and protect yourself and others,” said Jane L. Delgado, PhD, MS, President and CEO of the Alliance.
The wear a mask message was developed when Edgar Gil Rico, Senior Director for Innovation and Program Development at the Alliance was out for his daily run and noticed that most people did not use masks. “I run at 5am so as to allow for social distancing but I also use a mask. It was amazing to me how many people were not wearing a mask.” The importance of a mask has many dimensions. “You cannot tell by looking at someone whether or not they are carrying COVID19. Wearing a mask is what we do to protect each other,” emphasized Dr. Delgado.
To download the free messages and other COVID-19 information, go to healthyamericas.org or for the Spanish language version go to nuestrasalud.org.
About the National Alliance for Hispanic Health (The Alliance) — The Alliance is the nation’s foremost science-based source of information and trusted advocate for the health of Hispanics in the United States with a mission to achieve the best health for all. For more information visit us www.healthyamericas.org
Video – https://mma.prnewswire.com/media/1173139/FACEMASK_ENGLISHv2.mp4
SOURCE National Alliance for Hispanic Health
Julián Castro, Former HUD Secretary and Presidential Candidate, Joins Forces with Voto Latino; Voto Latino Commits to Registering over 1 Million Voters
WASHINGTON, May 26, 2020 /PRNewswire-HISPANIC PR WIRE/ — Today, Voto Latino announced that former Secretary of Housing and Urban Development and recent Presidential Candidate Julián Castro, will join forces with the organization as an advisor, supporting their efforts to engage the Latinx vote ahead of the November election. Castro’s experience and dedication to the social welfare and political organization of the Latinx community will be critical to accelerating Voto Latino’s work to uplift Latinx political power heading into the general election. Castro will add to the organization’s capacity to reach and influence the nation’s second-largest voting bloc.
“As I said during my campaign for president, the Latinx community will determine the outcome of November’s election,” said Secretary Castro. “At a time when Latinos are routinely targeted by the Trump administration and disproportionately hurt by the impact of COVID-19, Voto Latino is doing critical work to register and empower the 32 million eligible Latinx voters across the country. Their fifteen-year proven track record of registering Latinx voters using the most sophisticated, digital native campaigns has cultivated the trust of our community and has resulted in 79% of Voto Latino-registered voter turnout at the polls. I’m proud to partner with Maria Teresa and her team at Voto Latino in this effort, and look forward to Latinx voters saying ‘adios’ to Donald Trump in November.”
“Secretary Castro has been a champion of our community for years and Voto Latino is excited to welcome him,” said María Teresa Kumar, Founding President and CEO of Voto Latino. “This particular moment in history is one in which his unique perspective and counsel will be crucial to registering Latinx voters, protecting the health and safety of all voters across the country, and defeating Donald Trump. As we accelerate our proven systems and technology to register 1 million voters, Julián will hit the ground running to amplify Voto Latino’s mission in the halls of power.”
Secretary Castro joins the organization as Voto Latino launched the Immigrant Neighbor Fund, led a lawsuit in Texas against unconstitutional voting restrictions, and made its first-ever political endorsement.
Voto Latino is the nation’s largest political organization focused on registering and activating Latinx voters. Its grassroots efforts are focused on educating and empowering a new generation of Latinx voters, in addition to creating a more robust and inclusive democracy. Through innovative digital campaigns, culturally relevant programs, and authentic voices, we shepherd the Latinx community towards the full realization of its political power. Voto Latino is committed to registering 1 million voters for the 2020 political cycle.
Julián Castro served as U.S. Secretary of Housing and Urban Development under President Barack Obama. Before that, he was Mayor of his native city San Antonio, Texas — the youngest mayor of a Top 50 American city at the time. In 2012 he gave a rousing keynote speech at the Democratic National Convention, during which he described the American Dream as a relay to be passed from generation to generation. Secretary Castro launched a campaign for president in 2020 grounded in the belief that every American should count, and that Washington should put people—not big, special interests—first.
For more information, please contact Danny Turkel, [email protected].
Logo – https://mma.prnewswire.com/media/1172785/Voto_Latino_Logo.jpg
SOURCE Voto Latino
2021 Acura TLX Built on Dedicated Sport Sedan Architecture with Double Wishbone Front Suspension
TORRANCE, Calif., May 26, 2020 /PRNewswire-HISPANIC PR WIRE/ — The 2021 Acura TLX, to be digitally revealed on Thursday, May 28, is built on an all-new, Acura-exclusive sport sedan platform. The new TLX’s dedicated architecture is designed for Type S levels of performance and includes a highly rigid body and a performance-focused chassis highlighted by the return of double wishbone front suspension.
The new TLX’s front suspension uses two wishbone-shaped control arms, in place of the more common Macpherson strut setup in many competing sport sedans, to deliver more precise control of wheel camber, caster and toe angles, and to maximize tire-to-ground contact for exceptional handling precision and cornering grip. Due to its inherent performance-enhancing attributes, double wishbone suspension underpins the second-generation NSX supercar and was a staple of Acura performance products of the past, including the Legend (1986-1995), Integra (1990-2001), TL and TL Type S (1996-2014), and first-generation NSX (1991-2005).
The new TLX will make its public debut in a short film viewable at acura.com/2021-TLX on Thursday, May 28 at 10:00 a.m. PDT.
About Acura
Acura is a leading automotive nameplate that delivers Precision Crafted Performance – a commitment to evocative styling, high performance and innovative engineering, all built on a foundation of quality and reliability. The Acura lineup features five distinctive models –the TLX performance luxury sedan, the ILX sport sedan, the five-passenger RDX luxury crossover SUV, the seven-passenger Acura MDX, America’s all-time best-selling three-row luxury SUV, and the next-generation, electrified NSX supercar. All Acura models sold in North America for the 2021 model year are made in the U.S., using domestic and globally sourced parts.
Photo – https://mma.prnewswire.com/media/1172473/Acura_Chassis_Teaser_Final.jpg
Logo – https://mma.prnewswire.com/media/458749/acura_logo.jpg
SOURCE Acura
2021 Acura TLX Built on Dedicated Sport Sedan Architecture with Double Wishbone Front Suspension
TORRANCE, Calif., May 26, 2020 /PRNewswire-HISPANIC PR WIRE/ — The 2021 Acura TLX, to be digitally revealed on Thursday, May 28, is built on an all-new, Acura-exclusive sport sedan platform. The new TLX’s dedicated architecture is designed for Type S levels of performance and includes a highly rigid body and a performance-focused chassis highlighted by the return of double wishbone front suspension.
The new TLX’s front suspension uses two wishbone-shaped control arms, in place of the more common Macpherson strut setup in many competing sport sedans, to deliver more precise control of wheel camber, caster and toe angles, and to maximize tire-to-ground contact for exceptional handling precision and cornering grip. Due to its inherent performance-enhancing attributes, double wishbone suspension underpins the second-generation NSX supercar and was a staple of Acura performance products of the past, including the Legend (1986-1995), Integra (1990-2001), TL and TL Type S (1996-2014), and first-generation NSX (1991-2005).
The new TLX will make its public debut in a short film viewable at acura.com/2021-TLX on Thursday, May 28 at 10:00 a.m. PDT.
About Acura
Acura is a leading automotive nameplate that delivers Precision Crafted Performance – a commitment to evocative styling, high performance and innovative engineering, all built on a foundation of quality and reliability. The Acura lineup features five distinctive models –the TLX performance luxury sedan, the ILX sport sedan, the five-passenger RDX luxury crossover SUV, the seven-passenger Acura MDX, America’s all-time best-selling three-row luxury SUV, and the next-generation, electrified NSX supercar. All Acura models sold in North America for the 2021 model year are made in the U.S., using domestic and globally sourced parts.
Photo – https://mma.prnewswire.com/media/1172473/Acura_Chassis_Teaser_Final.jpg
Logo – https://mma.prnewswire.com/media/458749/acura_logo.jpg
SOURCE Acura
Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19
BRONX, N.Y., May 26, 2020 /PRNewswire-HISPANIC PR WIRE/– Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
In March, Montefiore was the first New York location to join the multicenter trial, which evaluated remdesivir, a broad-spectrum antiviral drug given intravenously. Preliminary results from the trial, announced last month, show that patients with COVID-19 who received remdesivir recovered in 11 days on average compared to 15 days for patients in the placebo group—a statistically significant improvement. Of the 1,063 clinical trial participants, 91 of them, nearly 10%, were from Montefiore and Einstein.
Following up on remdesivir’s promising results, the trial is now studying remdesivir in combination with baricitinib or placebo in a double-blind, randomized trial. Baricitinib is marketed for reducing inflammation associated with rheumatoid arthritis. Researchers want to know if baricitinib combined with remdesivir can prevent or reduce the hyper-inflammatory “cytokine storm” that can fatally overwhelm the lungs and other parts of the body in people with COVID-19 when their immune system reacts to coronavirus infection.
“What concerns us is that in some people the immune response to coronavirus can be more deadly than the infection itself, and there is no known treatment for this yet,” said Barry Zingman, M.D., professor of medicine at Einstein and clinical director, infectious diseases, at the Moses division of Montefiore Health System. “Including baricitinib in our trial may reduce COVID-19-related inflammation and combining baricitinib with remdesivir may yield an even more effective treatment option for people most severely affected by this illness.” Dr. Zingman oversaw the original remdesivir study at Montefiore and is directing ACTT 2.
Patients enrolled in ACTT 2 are hospitalized with a laboratory-confirmed coronavirus infection and lung complications, including rattling sounds when breathing, a need for supplemental oxygen, abnormal chest X-rays showing pneumonia, or the need for a mechanical ventilator. All patients will receive remdesivir intravenously for up to 10 days. Half of the patients will also be given baricitinib by mouth, with the remaining half receiving an identical placebo, both for up to 14 days.
Remdesivir was developed by Gilead Sciences, Inc. Baricitinib was developed by Eli Lilly and Company.
About Montefiore Health System
Montefiore Health System is one of New York’s premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children’s Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.
About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2019-20 academic year, Einstein is home to 724 M.D. students, 158 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 265 postdoctoral research fellows. The College of Medicine has more than 1,800 full-time faculty members located on the main campus and at its clinical affiliates. In 2019, Einstein received more than $178 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.
Click here to view a video of Dr. Zingman: https://www.youtube.com/watch?v=aLhOsg8LCSU&feature=youtu.be
Logo – https://mma.prnewswire.com/media/675671/Montefiore_Logo.jpg
SOURCE Montefiore Health System; Albert Einstein College of Medicine
Montefiore and Einstein Test a New Drug Combination to Conquer COVID-19
BRONX, N.Y., May 26, 2020 /PRNewswire-HISPANIC PR WIRE/– Montefiore Health System and Albert Einstein College of Medicine have begun the next stage of the Adaptive COVID-19 Treatment Trial (ACTT), to evaluate treatment options for people hospitalized with severe COVID-19 infection. The new iteration of the trial, known as ACTT 2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
In March, Montefiore was the first New York location to join the multicenter trial, which evaluated remdesivir, a broad-spectrum antiviral drug given intravenously. Preliminary results from the trial, announced last month, show that patients with COVID-19 who received remdesivir recovered in 11 days on average compared to 15 days for patients in the placebo group—a statistically significant improvement. Of the 1,063 clinical trial participants, 91 of them, nearly 10%, were from Montefiore and Einstein.
Following up on remdesivir’s promising results, the trial is now studying remdesivir in combination with baricitinib or placebo in a double-blind, randomized trial. Baricitinib is marketed for reducing inflammation associated with rheumatoid arthritis. Researchers want to know if baricitinib combined with remdesivir can prevent or reduce the hyper-inflammatory “cytokine storm” that can fatally overwhelm the lungs and other parts of the body in people with COVID-19 when their immune system reacts to coronavirus infection.
“What concerns us is that in some people the immune response to coronavirus can be more deadly than the infection itself, and there is no known treatment for this yet,” said Barry Zingman, M.D., professor of medicine at Einstein and clinical director, infectious diseases, at the Moses division of Montefiore Health System. “Including baricitinib in our trial may reduce COVID-19-related inflammation and combining baricitinib with remdesivir may yield an even more effective treatment option for people most severely affected by this illness.” Dr. Zingman oversaw the original remdesivir study at Montefiore and is directing ACTT 2.
Patients enrolled in ACTT 2 are hospitalized with a laboratory-confirmed coronavirus infection and lung complications, including rattling sounds when breathing, a need for supplemental oxygen, abnormal chest X-rays showing pneumonia, or the need for a mechanical ventilator. All patients will receive remdesivir intravenously for up to 10 days. Half of the patients will also be given baricitinib by mouth, with the remaining half receiving an identical placebo, both for up to 14 days.
Remdesivir was developed by Gilead Sciences, Inc. Baricitinib was developed by Eli Lilly and Company.
About Montefiore Health System
Montefiore Health System is one of New York’s premier academic health systems and is a recognized leader in providing exceptional quality and personalized, accountable care to approximately three million people in communities across the Bronx, Westchester and the Hudson Valley. It is comprised of 11 hospitals, including the Children’s Hospital at Montefiore, Burke Rehabilitation Hospital and more than 200 outpatient ambulatory care sites. The advanced clinical and translational research at its medical school, Albert Einstein College of Medicine, directly informs patient care and improves outcomes. From the Montefiore-Einstein Centers of Excellence in cancer, cardiology and vascular care, pediatrics, and transplantation, to its preeminent school-based health program, Montefiore is a fully integrated healthcare delivery system providing coordinated, comprehensive care to patients and their families. For more information please visit www.montefiore.org. Follow us on Twitter and view us on Facebook and YouTube.
About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation’s premier centers for research, medical education and clinical investigation. During the 2019-20 academic year, Einstein is home to 724 M.D. students, 158 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 265 postdoctoral research fellows. The College of Medicine has more than 1,800 full-time faculty members located on the main campus and at its clinical affiliates. In 2019, Einstein received more than $178 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.
Click here to view a video of Dr. Zingman: https://www.youtube.com/watch?v=aLhOsg8LCSU&feature=youtu.be
Logo – https://mma.prnewswire.com/media/675671/Montefiore_Logo.jpg
SOURCE Montefiore Health System; Albert Einstein College of Medicine